帕利哌酮缓释片治疗精神分裂症临床疗效和安全性研究  

Efficacy and safety of paliperidone extended-release tablets in the treatment of patients with schizophrenia

作　　者：丁国安[1] 余国汉[1] 马静山[1] 黄俊东[1] 李嘉[1] 梁绍材[1] 

机构地区：[1]广州市精神病医院,广州510370

出　　处：《中国新药杂志》2011年第12期1095-1097,共3页Chinese Journal of New Drugs

摘　　要：目的:观察可变剂量帕利哌酮缓释片治疗精神分裂症患者的疗效与安全性。方法:将79例精神分裂症住院患者给予帕利哌酮缓释片治疗6周,采用阳性与阴性症状量表(PANSS)、个人与社会功能量表(PSP)和副反应量表(TESS)作为评价指标。结果:研究组在治疗后第2周末及第6周末的PANSS各因子分及总分均低于基线时,基线时阳性症状因子分为(25.42±4.74),阴性症状因子分为(23.72±2.54),一般精神病理因子分为(23.72±2.54);第2周末阳性症状因子分为(19.14±5.26),阴性症状因子分为(18.19±4.43),一般精神病理因子分为(45.39±3.27);第6周末阳性症状因子分为(13.14±3.04),阴性症状因子分为(14.31±2.35),一般精神病理因子分为(58.92±5.35);差异均具有显著性意义(P<0.005)。研究组在治疗第6周末PSP总分(61.32±7.24)高于基线(48.83±6.64)时,增加(9.1±15.5),具有显著性意义(P<0.005)。帕利哌酮缓释片的主要不良反应为锥体外系不良反应(EPS)、失眠、便秘、泌乳素升高等。结论:帕利哌酮缓释片均可有效地改善精神分裂症的症状,提高个人和社会功能,并具有良好的耐受性。Objective： To explore efficacy and safety of palipefidone extended-release（ER） tablets in the treatment of patients with schizophrenia.Methods： Totally 79 schizophrenic patients were treated with paliperidone ER tablets for 6 weeks.They were assessed with Positive and Negative Symptoms Scales（PANSS）,Treatment Emergent symptom Scale（TESS） and Personal and Social Performance（PSP）.Results： In the end of the 2nd or 6th weeks of treatment with palipefidone ER tablets,the total and factor scores of PANSS were significantly lower than those in baseline（P0.05）,and the scores of PSP were significantly higher than those of control group（P0.05）.The common adverse events were extrapyramidal symptoms,insomnia,constipation and prolactin increasing in paliperidone ER group.Conclusion： Paliperidone ER tablets are effective to improve positive symptoms,negative symptoms and social functions of patients with schizophrenia with high safety.

关 键 词：帕利哌酮缓释片 精神分裂症 疗效 

分 类 号：R971.4[医药卫生—药品]